Literature DB >> 16905574

Transporting newborn infants with suspected duct dependent congenital heart disease on low-dose prostaglandin E1 without routine mechanical ventilation.

Kathryn A Browning Carmo1, Peter Barr, Maureen West, Neil W Hopper, Jennifer P White, Nadia Badawi.   

Abstract

AIM: To evaluate the safety of transporting newborn infants with suspected duct dependent congenital heart disease (CHD) treated with prostaglandin E1 (PGE1) without routine mechanical ventilation.
METHODS: A retrospective population-based audit of newborn infants with suspected CHD transported on PGE1 by the New South Wales newborn and paediatric Transport Service from 1995 through 2005.
RESULTS: Mechanical ventilation was not used prior to treatment with PGE1 in 94 (31%) of the 300 infants. The indications for mechanical ventilation in the remaining 206 infants (69%) included elective mechanical ventilation because of the intention to use PGE1 (n = 125) and severe hypoxaemia, acidosis or cardiorespiratory failure prior to commencing PGE1 (n = 81). 16 (17%) of the 94 infants who were not ventilated initially required mechanical ventilation before transport because of apnoea, which developed within one hour of commencing PGE1. 2 (2.6%) of the 78 infants transported without mechanical ventilation developed apnoea in transit and both were receiving >or=15 ng/kg/min of PGE1. Apnoea was more likely to occur in non-ventilated infants when the PGE1 infusion rate was >or=15 ng/kg/min compared with <15 ng/kg/min (14/33 vs 4/61, chi(2) = 15.55, p<.001).
CONCLUSIONS: Newborn infants with suspected duct dependent CHD treated with low dose PGE1 (<15 ng/kg/min) may not require mechanical ventilation for safe transport.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905574      PMCID: PMC2675450          DOI: 10.1136/adc.2006.096305

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  6 in total

1.  Management of the neonate with symptomatic congenital heart disease.

Authors:  D J Penny; L S Shekerdemian
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Long-distance transports of newborn infants with congenital heart disease.

Authors:  L Hellström-Westas; K Hanséus; P Jögi; N R Lundström; N Svenningsen
Journal:  Pediatr Cardiol       Date:  2001 Sep-Oct       Impact factor: 1.655

Review 3.  Fit to fly: practical challenges in neonatal transfers by air.

Authors:  C H Skeoch; L Jackson; A M Wilson; P Booth
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-11       Impact factor: 5.747

4.  Aminophylline for the prevention of apnea during prostaglandin E1 infusion.

Authors:  D S Lim; Thomas J Kulik; Dennis W Kim; John R Charpie; Dennis C Crowley; Kevin O Maher
Journal:  Pediatrics       Date:  2003-07       Impact factor: 7.124

5.  Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease.

Authors:  H H Kramer; M Sommer; S Rammos; O Krogmann
Journal:  Eur J Pediatr       Date:  1995-09       Impact factor: 3.183

6.  Study of low dosage prostaglandin--usages and complications.

Authors:  G K Singh; L V Fong; A P Salmon; B R Keeton
Journal:  Eur Heart J       Date:  1994-03       Impact factor: 29.983

  6 in total
  5 in total

Review 1.  Transporting babies with known heart disease; who, what and where?

Authors:  Frances A Bu'Lock
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-03       Impact factor: 5.747

2.  Routine mechanical ventilation for transferred neonates with duct-dependent congenital heart disease.

Authors:  Paola Ferrarese; Anna Marra; Nicoletta Doglioni; Vincenzo Zanardo; Daniele Trevisanuto
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09       Impact factor: 5.747

3.  Caffeine Citrate for the Prevention of Apnea Associated With Alprostadil Infusions.

Authors:  Kristi L Higgins; Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2020

4.  It Is Not Always Sepsis: Fatal Tachypnea in a Newborn.

Authors:  Rachel Levene; Elza Pollak-Christian; Ashish Garg; Michael Keenaghan
Journal:  Case Rep Pediatr       Date:  2018-02-21

Review 5.  Can Erythropoietin Reduce Hypoxemic Neurological Damages in Neonates With Congenital Heart Defects?

Authors:  Sara Ottolenghi; Giuseppina Milano; Michele Dei Cas; Tina O Findley; Rita Paroni; Antonio F Corno
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.